Wordt geladen...
Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation
Peroxisome proliferator-activated receptor γ (PPARγ) is a major therapeutic target for the treatment of type 2 diabetes. However, the use of PPARγ-targeted drugs, such as rosiglitazone and pioglitazone, is limited owing to serious side effects caused by classical agonism. Using a rational drug disco...
Bewaard in:
| Gepubliceerd in: | Sci Rep |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Publishing Group UK
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6671948/ https://ncbi.nlm.nih.gov/pubmed/31371757 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-47672-w |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|